Aurobindo Pharma in South Africa

Aurobindo Pharma’s Strategic Moves in South Africa: A Focus on HIV Prevention and Operational Restructuring

Johannesburg, South Africa – July 21, 2025

Aurobindo Pharma, a leading global pharmaceutical company, has recently undertaken significant initiatives in South Africa, emphasizing its commitment to enhancing healthcare access and optimizing its operational footprint.

Advancements in HIV Prevention

In March 2023, Aurobindo Pharma, alongside Cipla and Viatris, entered into sublicensing agreements with the Medicines Patent Pool (MPP) to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). This collaboration aims to provide low-cost, long-acting HIV prevention options to regions heavily impacted by the epidemic, including South Africa. Notably, Cipla has plans to manufacture this innovative prevention medicine within South Africa, potentially enhancing local production capabilities and accessibility. (cipla.co.za)

Operational Restructuring and Divestments

In October 2024, Aurobindo Pharma announced the divestment of its entire 50% stake in Novagen Pharma (Pty) Limited, a joint venture in South Africa. The sale was executed with Novabee Proprietary Limited, marking a strategic move to streamline operations and refocus the company’s investment strategy. Following this transaction, Aurogen South Africa (Pty) Ltd, a wholly owned subsidiary of Aurobindo, ceased to be a joint venture partner in Novagen. (business-standard.com)

Additionally, in May 2024, Aurogen South Africa entered into an agreement with the Rene Glyne Family Trust to sell its entire 24.5% stake in Purple Bellflower (PBF), another joint venture in South Africa. This divestment reflects Aurobindo’s ongoing efforts to optimize its global operations and concentrate on core business areas. (business-standard.com)

Conclusion

Aurobindo Pharma’s recent activities in South Africa underscore its dedication to improving healthcare outcomes through strategic partnerships and its commitment to operational efficiency. By focusing on innovative HIV prevention methods and refining its business operations, Aurobindo continues to play a pivotal role in the pharmaceutical sector, both locally and globally.